Enhancing Skin Cancer Early Detection and Treatment in Primary Care

Sponsor
OHSU Knight Cancer Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05675709
Collaborator
Oregon Health and Science University (Other), National Cancer Institute (NCI) (NIH)
80
1
2
17.9
4.5

Study Details

Study Description

Brief Summary

Skin cancer screening may help find melanoma sooner, when it may be easier to treat. If found early melanoma and other types of skin cancer may be curable. Multi-component education may be an effective method to help primary care physicians (PCPs) learn about skin cancer screening. This clinical trial examines whether a clinician-focused educational intervention can improve PCP's knowledge and clinical performance to identify and triage skin cancer. This intervention may increase the PCP's ability to diagnose, treat and/or triage early-stage melanoma.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Training and Education
N/A

Detailed Description

PRIMARY OBJECTIVE:
  1. Evaluate whether a multi-component education strategy improves the ability of PCPs to identify and triage skin cancer.
OUTLINE:

Participants are assigned to 1 of 2 groups.

PCP participants complete group training and online training sessions on study. Participants who complete the online training also take part in pre-post knowledge and confidence tests. A sub-group of providers will participate in a qualitative interview.

PCPs at the two clinics who are in pods that are not assigned to receive the intervention will serve as study comparators. Comparison group has no direct exposure to the group or online training sessions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Comparison group

PCPs at the two clinics who are in pods that are not assigned to receive the intervention will serve as study comparators. Comparison group has no exposure to the group or online training sessions.

Experimental: Other, Pragmatic

PCP participants complete group training and online training sessions on study. Participants who complete the online training also take part in pre-post knowledge and confidence tests. A sub-group of providers will participate in a qualitative interview.

Behavioral: Training and Education
Undergo group and online trainings

Outcome Measures

Primary Outcome Measures

  1. Reach of the educational intervention [6 months]

    Measured by proportion of clinicians invited to participate in the educational intervention that complete the training modules.

  2. Clinician knowledge and confidence in screening for skin cancer [6 months]

    Change in knowledge and confidence scores from pre to post training assessed via online survey.

  3. Use of risk assessment tool [18 months]

    Measured through electronic health record (EHR) data.

Secondary Outcome Measures

  1. Identification of suspicious lesions [18 months]

    Measured through EHR data.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Two Oregon Health & Science University (OHSU) primary care pods at two clinics will be assigned to receive exposure to the melanoma early detection intervention

  • Clinicians at the two clinics who are in pods that are not assigned to receive the intervention will serve as study comparators

  • These individuals are all aged 18 years or older

  • All practice members speak English

Exclusion Criteria:
  • No one will be intentionally excluded

Contacts and Locations

Locations

Site City State Country Postal Code
1 OHSU Knight Cancer Institute Portland Oregon United States 97239

Sponsors and Collaborators

  • OHSU Knight Cancer Institute
  • Oregon Health and Science University
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Susan A Flocke, Ph.D., OHSU Knight Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sue Flocke, Ph.D., Principal Investigator, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT05675709
Other Study ID Numbers:
  • STUDY00024809
  • NCI-2022-09484
  • STUDY00024809
  • P50CA244289
First Posted:
Jan 9, 2023
Last Update Posted:
Jan 9, 2023
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2023